A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Placebo in T2DM Patients

Exclusion Criteria

• •1. History of type 1 or other types of diabetes mellitus.
• •2. Use of any GLP-1 analogue during the 3 months preceding to screening.
• •3. History of proliferative diabetic retinopathy, diabetic maculopathy, diabetic neuropathy, or diabetic foot during the 6 months preceding screening.
• •4. History of acute or chronic pancreatitis or high risk factors for pancreatitis.
• •5. Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.
• •6. History of stomach surgeries or disorders associated with slowed emptying of the stomach during the past 6 months.
• •7. History of heart attack, stroke, or congestive heart failure of Grade 3 or 4 in the past 6 months.